CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma.
Like CD40L, agonistic anti-CD40 antibodies could activate and increase antigen presentation by APCs, leading to increased cytokine production, expression of other co-stimulatory molecules, and induction of cytotoxicity of effector T cells. CD40 activation on macrophages could reprogram these cells to relieve their immune suppressive activity. Agonistic anti-CD40 antibodies are thus an attractive prospect for use in cancer immunotherapy, where long-lasting specific anti-tumor T-cell responses are dictated by appropriately activated, antigen-loaded APCs, in particular DCs.
We are very proud to announce the first-in-human (FIH) dosing of LVGN7409 (CD40 agonist) on Jan 26, 2021 （NCT04635995）
If you as a patient or caregiver wish to participate in this study, please contact us at the following address: firstname.lastname@example.org or send us a message